Table 1.
Clinicohistopathological characteristics according to pathological results of patients enrolled in the study.
| Result | Benign (N = 374) | PTC (N = 159) | p value |
|---|---|---|---|
| Gender, female (%) | 300 (80.2) | 141 (88.7) | 0.018 |
| Age (years) | 45.33 ± 15.1 | 47.11 ± 12.8 | 0.194 |
| BMI (kg/m2) | 23.7 ± 3.7 | 24.2 ± 4.2 | 0.241 |
| TSH (mIU/L) | 1.6 ± 5.2 | 1.9 ± 1.4 | 0.702 |
| FT4 (ng/dl) | 1.8 ± 1.4 | 1.3 ± 0.7 | 0.003 |
| T4 (μg/dl) | 9.0 ± 8.8 | 7.8 ± 2.1 | 0.431 |
| T3 (ng/dl) | 144.0 ± 82.5 | 111.4 ± 29.6 | 0.007 |
| Anti-TPO Ab positive (%) | 66 (38.2) | 27 (29.7) | 0.172 |
| Anti-Tg Ab positive (%) | 10 (16.4) | 14 (20.0) | 0.598 |
| TRAb positive (%) | 84 (73.7) | 9 (29.0) | 0.000 |
| MicroPTC (%) | 34 (21.4) | ||
| Stage | 1 | 115 (72.3) | |
| 2 | 11 (6.9) | ||
| 3 | 12 (7.5) | ||
| 4 | 21 (13.2) | ||
| LN metastasis (%) | 47 (29.6) | ||
| Synchronous nonthyroidal malignancies or tumors (%) | 20 (12.6) |
PTC: papillary thyroid cancer; BMI: body mass index; TSH: thyroid-stimulating hormone; FT4: free thyroxine; T4: thyroxine; T3: triiodothyronine; anti-TPO Ab: thyroid peroxidase antibodies; anti-TG Ab: antithyroglobulin antibody; TRAb: TSH receptor antibody; HT: Hashimoto's thyroiditis; microPTC: papillary thyroid microcarcinoma; LN: lymph node.